Global Allogeneic CAR-T Cell Market to Grow at a CAGR of 15.6% During 2024-2032, Aided by the Growing Incidence of Cancer Diseases Across the Globe

Global Allogeneic CAR-T Cell Market Overview

Allogeneic CAR-T cells are genetically modified T-cells from a healthy with the purpose to specifically targeting and eliminating cancer cells in patients. Allogeneic CAR-T cells are "off-the-shelf" treatments that can be used on multiple patients, in contrast to autologous CAR-T cells, which are specific to each patient. The market growth is driven by technologies like CRISPR and TALEN which have decreased the risk of graft-versus-host disease (GVHD) and increased the effectiveness of allogeneic CAR-T therapies.

Key Findings

• Approximately 1.4 million cases of prostate cancer and around 2.2 million cases of lung cancer including other cancers are reported each year globally. The demand for allogeneic CAR-T cells is driven by the increasing scalability and safety of allogeneic therapies.
• The United States is likely to experience notable growth in the forecast period. The rising number of cancer cases, large investments from biotech and pharmaceutical companies as well as expanding collaborations between academia and industry play a crucial role in scaling the market value.
• In January 2024, CytoMed Therapeutics declared that they had received a patent for their CAR-γδ T cell technology from the Intellectual Property Corporation of Malaysia. This patent addresses techniques for gamma delta T cell expansion and modification to target a variety of cancers, including hematological and solid tumors. With prior patents in the United States and China, this broadens their portfolio of worldwide patents.

Global Allogeneic CAR-T Cell Industry Growth Drivers

The advancements in gene editing technologies that improve the safety and scalability of allogeneic treatments and allogeneic CAR-T cells are attractive to payers and healthcare providers due to their cost advantage, unlike autologous CAR-T therapy. This preference is boosting the growth of the market and boosting the number of patent applications. In September 2023, Allogene Therapeutics, a leader in the CAR-T space announced a licensing deal with Arbor Biotechnologies to develop gene-editing technologies and produce allogeneic CAR-T therapies of the next generation, especially for autoimmune diseases. By incorporating state-of-the-art gene-editing techniques to increase the effectiveness and safety of their treatments, this partnership expands Allogene's patent portfolio.

Segment Analysis

Market Segmentation Based on Type Areas is Anticipated to Witness Substantial Growth

Based on type, the market segmentation includes stem cells and non-stem cells. With the use of stem cell technology, allogeneic CAR-T cell therapy can produce T-cells from donor-derived stem cells, providing a reliable and expandable source of CAR-T cells. With less reliance on patient-specific cells, this method improves availability and increases the production of "off-the-shelf" therapies, which is further impacting the Allogeneic CAR-T Cell market value significantly.

CD19 Target Antigen is Expected to Lead the Market Share

Based on target antigens, the market constitutes CD19, BCMA, CD20, CD19/22 and others. In allogeneic CAR-T cell therapy, CD19 target antigen technology entails genetically modifying T-cells to express chimeric antigen receptors (CARs) that bind and recognize the CD19 protein on the surface of B-cells, including malignant ones. The CAR-T cells can efficiently target and eradicate B-cell cancers like lymphoma and leukemia by the action of the CD19 target antigen.

Competitive Landscape

• In June 2022, Precision BioSciences' revealed an ongoing allogeneic CAR-T program optimization for PBCAR0191 which targets patients who have relapsed after receiving CAR-T therapy. The product showed improvements in cell expansion and decreased lymphodepletion.
• In September 2023, the California Institute for Regenerative Medicine (CIRM) awarded a grant to Allogene Therapeutics. It was intended to help the development of ALLO-316, an allogeneic CAR-T therapy for treating renal cell carcinoma (RCC). This program has drawn attention for its innovative CD70 CAR technology and seeks to extend the use of CAR-T into solid tumors.
• Other players involved in the market are Immatics Biotechnologies Gmbh, Massachusetts Inst Technology, Novartis AG, Broad Inst Inc., Juno Therapeutics Inc., Iovance Biotherapeutics Inc., Gilead Sciences Inc., Dana Farber Cancer Inst Inc. and Cellectis, among others.

Regional Analysis

North America to Lead the Industry Share Based on Region

Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America, particularly the United States is witnessing increased collaborations and investments by key market players and advances in gene editing technologies. Growing awareness and adoption, owing to the cost-effectiveness of allogeneic CAR-T Cell therapy and treatment options is boosting the market growth in the region.

Key Offerings of the Report:

Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis for allogeneic CAR-T Cell technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with allogeneic CAR-T Cell.

Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for allogeneic CAR-T Cell and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for allogeneic CAR-T Cell and their relative value in the IP are covered in the final report.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790